CRISPR Therapeutics appoints Raju Prasad as CFO, replaces Brendan Smith

CRISPR Therapeutics AG

Raju Prasad, Ph.D., appointed CFO effective March 14, 2023; previously Partner at William Blair.
Annual salary $465,000, target bonus 45%, option grant for 100,000 shares, RSU grant for 40,000 shares.
Brendan Smith resigned as CFO effective March 13, 2023; no disagreement on financial reporting.
Smith remains employee through March 31, 2023, with continued equity vesting.
Prasad receives $100,000 one-time payment, forfeitable if terminated for cause before March 14, 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Raju Prasad

Chief Financial Officer

CRSP · CRISPR Therapeutics AG

Effective: 2023-03-14
Filed: March 14, 2023, 7:59 PM ET

On March 13, 2023, CRISPR Therapeutics AG (the “Company”) announced the hiring and appointment of Raju Prasad, Ph.D. as its Chief Financial Officer, effective March 14, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Raju Prasad was appointed as Chief Financial Officer at CRISPR Therapeutics AG.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On March 13, 2023, CRISPR Therapeutics AG (the “Company”) announced the hiring and appointment of Raju Prasad, Ph.D. as its Chief Financial Officer, effective March 14, 2023.

View on SEC.gov

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-23-007716

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.